Literature DB >> 15734285

Analyses of a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.

Daisuke Harada1, Chie Takada, Yukihito Tsukumo, Katsumi Takaba, Haruhiko Manabe.   

Abstract

BACKGROUND: The model of chronic dermatitis caused by repeated application of hapten is frequently used as a tool for assessment of the efficacy of a compound or the elucidation of chronic dermatitis.
OBJECTIVE: The purpose of this study is to provide more detailed analysis of the model of chronic dermatitis caused by repeated application of 2,4,6-trinitro-1-chlorobenzene (TNCB).
METHODS: BALB/c mice were sensitized with TNCB on day -7 to the ear, and then TNCB was repeatedly applied to the same ear three times per week, through days 0-21.
RESULTS: The repeated application of TNCB induced an increase of ear thickness, and a relatively steep increment of ear thickness from days 7 to 9 was observed. This increment reached almost a plateau at day 9. The peaks of ear swelling on days 7, 14 and 21 were approximately two times higher than that on day 0. Regarding cytokines in the ear, the highest production of IL-1 beta, 4, 6 and 18 were observed on day 7. The peak production of IL-1 beta, 4 and 6 on day 7 was found within 24 h after the challenge, while that of IL-18 was found at 0 h. The inflammatory cell infiltration into epidermis and dermis was observed and increased in day 7, then reached almost a plateau on day 9.
CONCLUSION: The indices such as thickness, swelling and inflammatory cell infiltration in the lesional skin was increased and maintained by repeated application, however, the protein levels of some cytokines were not always consistent with the reactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15734285     DOI: 10.1016/j.jdermsci.2004.11.007

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  8 in total

1.  Suppression of cytokine gene expression and improved therapeutic efficacy of microemulsion-based tacrolimus cream for atopic dermatitis.

Authors:  Manisha S Lalan; Naresh C Laddha; Jigar Lalani; Muhammad J Imran; Rasheedunnisa Begum; Ambikanandan Misra
Journal:  Drug Deliv Transl Res       Date:  2012-04       Impact factor: 4.617

2.  Anti-allergic activities of Umbelliferone against histamine- and Picryl chloride-induced ear edema by targeting Nrf2/iNOS signaling in mice.

Authors:  Ashrafullah Khan; Omer Shehzad; Eun Kyoung Seo; Alev Onder; Salman Khan
Journal:  BMC Complement Med Ther       Date:  2021-08-27

Review 3.  The potential action of SSRIs in the treatment of skin diseases including atopic dermatitis and slow-healing wounds.

Authors:  Aneta Kiecka; Marian Szczepanik
Journal:  Pharmacol Rep       Date:  2022-10-07       Impact factor: 3.919

4.  Prevention of diabetes in NOD mice by repeated exposures to a contact allergen inducing a sub-clinical dermatitis.

Authors:  Kaare Engkilde; Karsten Buschard; Axel Kornerup Hansen; Torkil Menné; Jeanne Duus Johansen
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

5.  Extract from peel of Citrus natsudaidai alleviates experimental chronic allergic dermatitis in mice.

Authors:  Noriyuki Nakayama; Katsunori Yamaura; Maki Shimada; Koichi Ueno
Journal:  Pharmacognosy Res       Date:  2011-07

6.  Anti-Inflammatory Effect of Titrated Extract of Centella asiatica in Phthalic Anhydride-Induced Allergic Dermatitis Animal Model.

Authors:  Ju Ho Park; Ji Yeon Choi; Dong Ju Son; Eun Kyung Park; Min Jong Song; Mats Hellström; Jin Tae Hong
Journal:  Int J Mol Sci       Date:  2017-03-30       Impact factor: 5.923

7.  Chronic Toxoplasmosis Modulates the Induction of Contact Hypersensitivity by TNCB in Mouse Model.

Authors:  Zhaoshou Yang; Hye-Jin Ahn; Ho-Woo Nam
Journal:  Korean J Parasitol       Date:  2015-12-31       Impact factor: 1.341

8.  Fluoxetine Ameliorates Atopic Dermatitis-Like Skin Lesions in BALB/c Mice through Reducing Psychological Stress and Inflammatory Response.

Authors:  Yanxi Li; Long Chen; Yehong Du; Daochao Huang; Huili Han; Zhifang Dong
Journal:  Front Pharmacol       Date:  2016-09-13       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.